Participated · Series D · Aug 2026

Hopscotch Primary Care operates a technology-enabled primary care model serving rural communities across the southeastern United States. Founded in 2021, the company serves more than 15,000 patients through 12 clinical locations, with its largest concentration in rural Western North Carolina. Its model emphasizes same-day visits, 24/7 access to care teams, and proactive outreach supported by administrative and clinical technology. Hopscotch reports strong patient-facing metrics—Net Promoter Score of 89 and patient retention above 90%—and says it has driven medical-loss-ratio improvement of over 25 percentage points for patients in their first two years. That operating performance is already translating to profitable operations in Western North Carolina. The company plans to use recent funding to expand into additional rural markets and continue scaling its technology-powered operations.

Participated · Debt Financing · Jul 2026

Stealth BioTherapeutics focuses on developing therapies that directly address mitochondrial bioenergetic deficits across rare and age-related diseases. The company’s development portfolio includes elamipretide programs in Barth syndrome, polymerase gamma–related mitochondrial disease and dry age-related macular degeneration, a next-generation clinical candidate bevemipretide for ophthalmic and neurological indications, and preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. Its parent, Mighty Therapeutics, achieved FDA approval in September 2025 for the first commercial therapy for Barth syndrome and the first FDA-approved therapy to directly target mitochondria, generating revenue from its lead commercial product. The company plans to use newly secured capital to accelerate commercial launch activities and advance late-stage and pipeline development programs. Financially, current cash, cash equivalents and product revenues are expected to extend runway into 2028, with additional financing drawdowns projected to support cash flow positivity in early 2029.

Participated · Equity · Feb 2026

Founded in 2021, Honest Health partners with hospitals and provider groups to navigate value-based, risk-bearing reimbursement models. Its platform supplies clinicians with actionable analytics, operational support, and shared-accountability structures that prioritize quality and cost containment over volume. Led by CEO Rob Bessler, M.D., and backed by founders from Rubicon Founders, the company combines deep clinical expertise with scalable technology infrastructure. Honest Health’s services include care coordination tools and performance dashboards designed to improve patient outcomes and financial performance for health systems. The company has rapidly gained traction, prompting sizable investor interest. Proceeds from its latest funding will be used to expand into additional U.S. markets, form new partnerships with payers and providers, and further develop its technology and service offerings. No revenue or user metrics were disclosed in the article, but management cites “measurable improvements” in outcomes and cost savings as evidence of early success.

Participated · Series A · Jan 2026

Founded in 2024, Zarminali Pediatrics is building a national multispecialty pediatric health system that unifies primary, specialty, and urgent care under one technology-driven platform. The company currently runs 28 outpatient clinics across eight states and positions itself as a single destination for families seeking comprehensive pediatric services. Its proprietary technology backbone supports coordinated care and alleviates administrative burdens for clinicians, while enhancing access for patients through features such as planned 24/7 telehealth. In 2026, Zarminali intends to open 15 additional de novo clinics in new markets including Chicago, Milwaukee, and Dallas and to broaden its service mix to speech, occupational, and behavioral health therapies. The model emphasizes family-centered design, empowered clinicians, and seamless care coordination. Following its $110 million Series A, the company has raised $150 million in total funding to fuel rapid clinic expansion and technology development.

Participated · Series B · Jan 2026

Apella Technology has built an "ambient video intelligence" layer for procedural environments, beginning with the operating room. Its platform uses computer vision and machine learning to automatically detect and label up to 14 surgical case events and then write that data directly into the electronic health record, cutting manual documentation and improving situational awareness. Hospitals deploying Apella report an average 5 % rise in surgical volume as better coordination unlocks capacity and reduces delays. Houston Methodist, a nine-hospital system, expanded from a 36-room pilot to more than 200 operating rooms, illustrating enterprise-scale adoption. The company has also extended its technology to interventional radiology, cardiology and endoscopy suites for broader operational visibility. A new module, Horizon, delivers more accurate case-duration estimates and utilization predictions to optimize scheduling before each day begins. Apella positions itself within the growing "ambient AI" trend in healthcare and was named to Fast Company’s 2025 Most Innovative Companies list.